1. Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
   Yosuke Miura et al, 2017, Oncology Letters CrossRef
2. Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer
   Shoko Norimura et al, 2018, Journal of Cancer Research and Therapeutics CrossRef
3. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis
   YONGKANG YU et al, 2014, Experimental and Therapeutic Medicine CrossRef
4. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
   Marianna Macerelli et al, 2016, Cancer Treatment Reviews CrossRef
5. Use of TUBB3 for Patient Stratification and Prognosis in Lung Cancer
   Jan Nyrop Jakobsen et al, 2015, Lung Cancer Management CrossRef
6. The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis
   Yan-Long Yang et al, 2014, PLoS ONE CrossRef